Navigation Links
Barr Confirms Patent Challenge of Focalin(R) XR
Date:11/20/2007

products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; our expansion into international markets through our PLIVA acquisition, and the resulting currency, governmental, regulatory and other risks involved with international operations; our ability to service our significantly increased debt obligations as a result of the PLIVA acquisition; changes in generally accepted accounting principles; and other risks detailed in our SEC filings, including in our Transition Report on Form 10-K/T for the six months ended December 31, 2006.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.


'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
4. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. Pressure BioSciences, Inc. Issued First Patent in Canada
7. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
8. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
9. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
10. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
11. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  Quest Diagnostics Incorporated ... diagnostic information services, announced that it is scheduled to ... New York.  Steve Rusckowski , the company,s President ... five point strategy.  The presentation is scheduled for Tuesday, ... The presentation will be webcast live during the ...
(Date:5/28/2015)... 27, 2015 Research and Markets( ... Jain PharmaBiotech,s new report "Nanobiotechnology Applications, ... An increasing use of nanobiotechnology ... anticipated. Nanotechnology will be applied at all ... for optimal delivery to diagnostic applications in ...
(Date:5/28/2015)... DUBLIN , May 27, 2015 ... addition of Jain PharmaBiotech,s new report "Cell ... their offering. This report describes and ... already started to play an important role in ... is replacing the old fashioned bone marrow transplants. ...
(Date:5/28/2015)... 28, 2015 The Academy of Model Aeronautics ... Day on August 15, 2015. National Model Aviation Day was ... to introduce model flying to the general public. , The ... to participate in the celebration by hosting events in their ... National Model Aviation Day events. View our online event ...
Breaking Biology Technology:Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2
... clinical trials of its treatment for ... inflammatory bowel disease., OKLAHOMA CITY, ... capital financing to fund clinical trials,testing the efficacy of its therapy ... the round and was joined by the,Oklahoma Seed Capital Fund and ...
... Sept. 18 The future of health care ... into practice and,health policy. But putting research into ... the pace of cutting-edge care. Kaiser,Permanente Colorado is ... at getting research into practice and policy more,quickly ...
... (Nasdaq: ONXX ) today announced that it ... on Monday, September 24, at 9:00,a.m. Eastern Time. ... the,presentation at: http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070924 It ... early in order to,register and download any necessary ...
Cached Biology Technology:Altheus Therapeutics Secures $3.6 Million in Venture Capital 2Kaiser Permanente Colorado Opens Center for Health Dissemination and Implementation Research 2
(Date:5/26/2015)... May 26, 2015 Research ... addition of the "Saudi Arabia Biometric Systems ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric ... is projected to grow at over 22% ... is attributed to the surging demand for better ...
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... similar to a drug used in the treatment of Parkinson's ... be used to develop drug therapy for cocaine abuse, new ... 23, 2005, issue of The Journal of Neuroscience, Jonathan Katz ... (NIDA) report the results of experiments showing that mice treated ...
... identified the proteins that allow specific brain cells to "change ... the cell. The findings, described in the March 24 issue ... day using it to protect cells that die in Lou ... what comes into the living room, these brain cells are ...
... identifies a critical inhibitory step that is a ... balance between neutrophil production and destruction. The research, ... that the process for disposal of dying neutrophils ... understanding of the processes that control neutrophil turnover ...
Cached Biology News:Potential Drug Target For Treating Cocaine Abuse Found 2Some Brain Cells 'Change Channels' To Fine-tune The Message 2Some Brain Cells 'Change Channels' To Fine-tune The Message 3White Blood Cell 'Waste Disposal' System Plays Critical Regulatory Role 2
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... Assay, 96 wells. ELISA.Specific for total ... MMP-3. No cross-reactivity with MMP-1, -2, -9. ... use with cell culture supernatant, serum, plasma ... to -30 C. Category: Drug Screening ...
... Steady gravity-fed delivery of buffer and ... perfusion. Rat version. In Vivo Manual ... gravity-fed delivery of buffer and fixative ... to setup, use and clean--Complete system ...
Biology Products: